

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## SCHEDULE 13G (Rule 13d-102)

Information statement pursuant to Rules 13d-1 and 13d-2

**Under the Securities Exchange Act of 1934**  
(Amendment No.)

**Sinovac Biotech Ltd.**

(Name of Issuer)

**Common Stock**  
(Title of Class of Securities)

**P8696W104**  
(CUSIP Number)

Date of Event Which Requires Filing of this Statement: December 31, 2010

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. P8696W104 13G  
1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Royce & Associates, LLC 52-2343049  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a) [ ]  
(b)  
3 SEC USE ONLY  
4 CITIZENSHIP OR PLACE OF ORGANIZATION  
New York  
NUMBER OF 5 SOLE VOTING POWER  
SHARES 3,525,129  
BENEFICIALLY 6 SHARED VOTING POWER  
OWNED BY  
EACH 7 SOLE DISPOSITIVE POWER

---

REPORTING 3,525,129  
PERSON 8 SHARED DISPOSITIVE POWER  
WITH  
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
PERSON 3,525,129  
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)  
EXCLUDES CERTAIN SHARES [ ]  
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
6.51%  
12 TYPE OF REPORTING PERSON  
IA

CUSIP No. P8696W104 13G  
Item 1(a) Name of Issuer:  
Sinovac Biotech Ltd.

Item 1(b) Address of Issuer's Principal Executive Offices:  
Chief Financial Officer  
39 Shangdi Xi Road  
China,

Item 2(a) Name of Persons Filing:  
Royce & Associates, LLC

Item 2(b) Address of Principal Business Office, or, if None,  
Residence:  
745 Fifth Avenue, New York, NY 10151

Item 2(c) Citizenship:  
New York Corporation

Item 2(d) Title of Class of Securities:  
Common Stock

Item 2(e) CUSIP Number:  
P8696W104

Item 3 If this statement is filed pursuant to rules 13d-1(b), or  
13d-

2(b), check whether the person filing is a:

- (a) [ ] Broker or Dealer registered under Section 15 of the Act  
(b) [ ] Bank as defined in Section 3(a)(6) of the Act  
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the  
Act  
(d) [ ] Investment Company registered under Section 8 of  
the Investment Company Act  
(e) [X] Investment Adviser registered under Section 203 of  
the Investment Advisers Act of 1940  
(f) [ ] Employee Benefit Plan, Pension Fund which is  
subject to the provisions of the Employee  
Retirement Income Security Act of 1974 or Endowment Fund  
(g) [ ] Parent Holding Company, in accordance with Rule 13d-1  
(b)(ii)(G)  
(h) [ ] Group

CUSIP No. P8696W104 13G

Item 4 Ownership

(a) Amount Beneficially Owned:  
3,525,129

(b) Percent of Class:  
6.51%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote  
3,525,129

(ii) shared power to vote or to direct the vote

---

- 
- (iii) sole power to dispose or to direct the disposition  
of 3,525,129
- (iv) shared power to dispose or to direct the  
disposition of \_\_\_\_\_
- Item 5 Ownership of Five Percent or Less of a Class. [ ]
- Item 6 Ownership of More than Five Percent on Behalf of Another  
Person .
- NOT APPLICABLE
- Item 7 Identification and Classification of the Subsidiary Which  
Acquired  
The Security Being Reported on by the Parent Holding  
Company.
- NOT APPLICABLE
- Item 8 Identification and Classification of Members of the Group.  
NOT APPLICABLE
- Item 9 Notice of Dissolution of Group.  
NOT APPLICABLE

CUSIP No. P8696W104 13G  
Item 10 Certification.

By signing below I certify that, to the best of my knowledge and  
belief,  
the securities referred to above were acquired and are held in the  
ordinary  
course of business and were not acquired and are not held for the  
purpose of  
or with the effect of changing or influencing the control of the  
issuer of  
the securities and were not acquired and are not held in connection  
with  
or as a participant in any transaction having that purpose or  
effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief,  
I certify that the information set forth in this statement with  
respect  
to it is true, complete and correct.

Date: February 04, 2011

By: John E. Denneen, Secretary